High Intrinsic Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome

• Published in: Animals (Basel) Vol. 11; no. 3; p. 658
• Main Authors: Levi, Michela, Muscatello, Luisa Vera, Brunetti, Barbara, Benazzi, Cinzia, Parenti, Federico, Gobbo, Francesca, Avallone, Giancarlo, Bacci, Barbara, Zambon, Elisa, Valenti, Paola, Sarli, Giuseppe
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02-03-2021; MDPI
• Subjects: ABC transporters; Antibodies; Antigens; Archives & records; Breast cancer; breast cancer resistance protein; Cancer therapies; canine mammary carcinoma; Chemotherapy; Dogs; Drugs; Epidermal growth factor; Epidermal growth factor receptors; ErbB-2 protein; Estrogen receptors; Estrogens; Glycoproteins; Growth factors; Immunohistochemistry; immunophenotypes; Mammary gland; Medical prognosis; Molecular modelling; Multidrug resistance; P-Glycoprotein; Phenotypes; Progesterone; Progesterone receptors; Proteins; Surgery; Tumors; United States > US; P-glycoprotein; multidrug resistance; breast cancer resistance protein; canine mammary carcinoma; immunophenotypes
• ISSN: 2076-2615; 2076-2615
• DOI: 10.3390/ani11030658

P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are major actors in multidrug resistance (MDR) phenomenon in both human and canine mammary carcinomas (CMCs). The aim of this study was to investigate an association between the intrinsic expression of P-gp and BCRP compared to the immunophenotypes and outcome in CMCs. Fifty CMCs were evaluated at immunohistochemistry (IHC) for P-gp, BCRP, Estrogen receptor alpha (ER), Progesterone receptors (PR), Human Epidermal Growth Factor Receptor type 2 (HER2), basal cytokeratins 5/6 (CK5/6), Epidermal Growth Factor Receptor 1 (EGFR), and Ki67 proliferation index. P-gp and BCRP positive cases were, respectively, 52% and 74.5%, with a significantly higher expression of BCRP than P-gp. Five immunophenotypes were defined in 37 out of 50 CMCs: 9 (24.3%) Luminal A, 5 (13.5%) Luminal B, 9 (24.3%) HER2 overexpressing, 9 (24.3%) Triple-negative basal-like, and 5 (13.5%) Triple-negative non-basal-like. In all CMCs at least one marker was expressed. Follow-up data were available for 25 animals. The average cancer-specific survival was 739 ± 444 days. A number of CMCs bear a high expression of P-gp and BCRP but no significant association was found between their expression and the immunophenotypes, Ki67 index, the histological grade, and tumor-related death.